Back

Experts review the epidemiology and drivers of hidradenitis suppurativa, the clinical, emotional, and economic toll on patients, and how the treatment landscape is evolving.

Optimizing Ponatinib Use in Philadelphia Chromosome–Positive ALL

Episodes

Specialty:

All

Year:

All

EP. 1: Setting the Stage: Ph+ ALL, the Need for Prompt Treatment, and GIMEMA

ByShawn Griffin, PharmD, BCOP,Samantha Maples, PharmD, BCOP

November 11th 2026

The question in frontline Ph+ ALL is no longer whether to use a TKI. It’s which one, and what to pair it with.

Optimizing Ponatinib Use in Philadelphia Chromosome–Positive ALL

Episodes

EP. 1: Setting the Stage: Ph+ ALL, the Need for Prompt Treatment, and GIMEMA

Trending on Pharmacy Times

Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction

mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients

FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk

Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care

Mavacamten Benefit Holds at 56 Weeks in Adolescents With oHCM